Paul M. Copeland, MD
- 4Articles
- 13.2KReads1
- 2005–2007Active
- 18Collaborators
About
Paul M. Copeland, MD, has published extensively on metabolic disorders in patients with schizophrenia and schizoaffective disorders. His work focuses on glucose metabolism, diabetes mellitus, and cardiovascular risks associated with atypical antipsychotic treatments such as clozapine, olanzapine, and quetiapine. Copeland’s research includes clinical studies on hemoglobin A1c as an indicator of diabetes and guidelines addressing medical morbidity and mortality in schizophrenia.
Publications
1 Read counts for articles published before 2020 may include some non-human traffic.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
